The study of fatigue as a major focus in clinical practice and research is relatively new, but the editors argue that much more is known about it than most texts admit. Here two dozen essays and interviews represent the perspectives of clinically oriented people, who often go beyond the established

Fatigue in Cancer: A Multidimensional Approach

Health, Fitness & Dieting

Barton-Burke, Margaret

Diseases & Physical Ailments

Jones& Bartlett Learning

This abbreviated edition of the larger textbook presents the most commonly used cancer chemotherapeutic agents. It includes all side effect information for 45-plus drugs in easy-to-read tables and appendices, as well as care plans (diagnosis, defining characteristics, expected outcomes, and specific interventions) for each medication and 13 related toxicities. The appendices comprise a chemotherapy checklist and nursing guidelines, extravasation, hypersensitivity and anaphylactic reactions, and an illustrated guide to handling cytotoxic and hazardous drugs. Spiral binding. Annotation c. Book News, Inc., Portland, OR (booknews.com)

Cancer Chemotherapy Care Plans Handbook

Wukjes, Gail M.

Ingwersen, Karen

This comprehensive reference is designed for the generalist nurse administering cancer therapy in non-oncology settings such as medical and surgical floors. Major topics include chemotherapy, biotherapy, moleculary targeted therapies, transplants, therapy in the non-malignant condition, a brief overview of drugs, safe administration, and competency issues and resources. There is no other reference currently available that specifically covers all of the Cancer Therapies in one resource and provides information on nursing management.

Cancer Therapies

Medical Books

Wilkes, Gail M.

Nursing

2008 Oncology Nursing Drug Handbook is a comprehensive nursing resource for assessment, intervention, and patient education in the administration of oncology drugs. This text reviews drug information from the nurse's point of view, and helps the nurse focus on minimizing toxicity. This essential reference provides valuable information on effective symptom management and chemotherapy administration for the oncology nurse. Revised annually with new drugs, the book also includes updated indications and additional toxicology data for individual drugs.

Oncology Nursing Drug Handbook 2008

Oncology Consulting Services, Boston, MA. Second edition of a clinical reference for practitioners. Previous edition 1991. Emphasizes the nursing process, including diagnosis and care plans. Concise format. Extensive use of charts. 13 U.S. contributors. DNLM: Neoplasms - nursing.

Cancer Chemotherapy: A Nursing Process Approach (Jones & Bartlett Series in Nursing)

Ingwersen, Karen C.

Bean, Catherine K.

Berg, Deborah

Written especially for nurses caring for patients with cancer, the 2014 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2014 Oncology Nursing Drug Handbook includes: * New chapter on Chemobiotherapy for Noncancer Diseases * Specific drugs described in terms of their mechanism of action, metabolism, drug interactions, laboratory effects/interference, and special considerations * The most important and common drug side effects * Greater discussion of fundamentals of malignant transformation, new molecular targets, and drugs in the pipeline New drug entries include: enzalutamide, omacetaxine (Synribo), tbo-filgrastim (Netroval), ado-trastuzumab emtansine, aflibercept, bosutinib, cabozantinib, carfilzomib, dabrafenib, pomalidomide, ponatinib, regorafenib, trametinib, abatacept (Orencia), adalimumab (Humira), certolizumab pegol (CIMZA), etanercept (Enbrel), golimumab (Simponi), infliximab (Remicade), tocilizumab (Actemra), and tofacitinib (Xeljanz).

2014 Oncology Nursing Drug Handbook

Written especially for nurses caring for patients with cancer, the 2015 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2015 Oncology Nursing Drug Handbook includes a simplified chapter on molecular and biological targeted therapy that incorporates new information about immunotherapy, new indications, and the most important and common side effects. New drug entries include: afatinib, belinostat, ceritinib, ibrutinib, idelalisib, obinutuzumab, pembrolizumab, ramucirumab, siltuximab, and mercaptopurine oral suspension.

2015 Oncology Nursing Drug Handbook

Written especially for nurses caring for patients with cancer, the 2016 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2016 Oncology Nursing Drug Handbook includes a simplified chapter on molecular and biological targeted therapy that incorporates new information about immunotherapy, new indications, and the most important and common side effects.

2016 Oncology Nursing Drug Handbook

Written especially for nurses caring for patients with cancer, the 2017 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2017 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs. New drugs include: alectinib (Alecensa), atezolizumab (Tecentriq), cabozantinib tablets (Cabometyx), cabozantinib capsules (Cometriq), cobimetinib tablets (Cotellic), colistin/polymixin B, clotrimazole, daratumumab (Darzalex), elotuzumab (Empliciti), irinotecan liposome injection (Onivyde), ixazomib (Ninlaro), melphalan for injection (Evoela), necitumumab (Portrazza), osimertinib (Targrisso), pentamidine, posaconazole, peramivir, rolapitant (Varubi) , talimogene laherparepvec (Imlygic), Tamiflu, trabectedin (Yondelis), uridine triacetate (Vistogard granules), venetoclax (Venclexta), vincristine liposome injection (Marqibo), and zanamivir.

2017 Oncology Nursing Drug Handbook

Written especially for nurses caring for patients with cancer, the 2018 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2018 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs. New drugs include: avelumab (Bavencio), brigatinib (Alunbrig), durvalumab (Imfinzi), enasidenib (Idhifa), metronidazole hydrochloride (Flagyl), midostaurin (Rydapt), neratinib (Nerlynx), niraparib (Zejula), olaratumab (Lartruvo), ribociclib (Kisqali), rituximab and hyaluronidase human injection (Rituxan Hycela injection), rucaparib (Rubraca), telotristat ethyl (Xermelo), and tisagenlecleucel (Kymriah).

2018 Oncology Nursing Drug Handbook

See the best price to sell, buy, or rent books by Barton-Burke, Margaret. BookScouter helps to compare book prices from 25+ online bookstores and 30+ buyback vendors with a single search.

Books by Barton-Burke, Margaret